Patent classifications
A61P1/06
METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS
The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
Composition comprising HMOs for preventing or reducing nociception
The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).
FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN THE GUT
The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.
COMPOSITION AND METHOD FOR TREATING HUMANS USING LOW-FODMAP DIETS
A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.
FUSED HETEROTRICYCLIC ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF
The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.
Methods for treating GI tract disorders
Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
Flavanones for use in treating visceral hypersensitivity
The present invention relates to compounds of formula (I), such as hesperitin-7-rutinoside 2S, for use in the treatment of visceral hypersensitivity. Compounds and compositions of the invention are particularly useful in the treatment of visceral hypersensitivity in a subject having irritable bowel syndrome or age-associated low grade systemic inflammation of the gut, but lacking spasmodic intestinal contractions.
4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
Kappa opioid agonists and uses thereof
Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof: ##STR00001## The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
COMPOUNDS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND METHODS THEREOF
The current application relates to the use of emoxypine or a glutamate 2b receptor (Glut2B) antagonist for the treatment or prophylaxis of colitis or inflammatory bowel disease (IBD) in a subject. The glut2B antagonist or emoxypine can also be combined with other drugs such as anti-inflammatory drugs, immune system suppressors, antibiotics, anti-diarrheas, pain relievers, iron supplements, vitamin B12, or calcium/vitamin D supplements.